Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2021-02-03 Declaration of Voting R…
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the number of shares and voting rights as of January 31, 2021. This content directly relates to reporting changes in share capital and voting rights, which aligns with the definition of a Major Shareholding Notification (MRQ) or, more specifically given the context of capital structure reporting, a filing related to share capital changes. However, the most precise fit among the provided codes for a regular monthly disclosure of the total number of shares and voting rights is often captured under general capital/share structure updates. Since the document is a formal regulatory disclosure about the total number of shares and voting rights, it is a specific type of capital structure update. While 'SHA' (Share Issue/Capital Change) is related, this is a routine monthly disclosure of the *current* total, not necessarily an announcement of a new issue or change event. Given the options, this type of mandatory disclosure about the total share count and voting rights is often grouped with capital structure reporting. Let's re-evaluate the options: 'SHA' is for 'New share issues, stock splits, or other capital changes.' 'MRQ' is for 'Notification of changes in significant share ownership levels (crossing thresholds).' This document reports the *total* capital structure, not just crossing a threshold by a major shareholder. Since it is a formal, periodic report on the capital structure itself, and not a general regulatory filing (RNS) or a specific dividend/transaction report, it best fits under Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA) if interpreted broadly as a capital structure report. Given the explicit focus on the total number of shares and voting rights, it is a direct report on the capital structure. In many regulatory contexts, this specific monthly disclosure is a required update on the capital base. 'SHA' seems the most appropriate fit for a formal report detailing the current state of the share capital base, even if it's a routine update rather than a one-off event announcement.
2021-02-03 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated February 2, 2021, announcing that MedinCell has selected lead formulations and started the 'regulatory preclinical development' for three new long-acting injectable treatments (mdc-GRT, mdc-KPT, mdc-TTG). It details the status of these pipeline products and mentions future regulatory steps (first-in-human study, clinical trials). This type of announcement, focusing on R&D progress, pipeline updates, and regulatory milestones, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a formal announcement detailing strategic pipeline progress rather than just financial results (ER) or a formal legal filing, 'Investor Presentation' (IP) is the most fitting category, as these often contain detailed pipeline updates intended for investors. It is not a formal regulatory filing like 10-K or IR, nor is it a simple earnings release or a report publication announcement (RPA).
2021-02-02 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated February 2, 2021, announcing that MedinCell is entering the regulatory development phase for three new long-acting injectable products (mdc-GRT, mdc-KPT, mdc-TTG). It details pipeline progress, quotes the Chairman, and provides portfolio context. This type of announcement, focusing on R&D milestones and pipeline updates, is best classified as a general corporate update or news release. Since there is no specific category for R&D pipeline updates, and it is not a formal financial report (10-K, IR, ER), nor a management change (MANG) or dividend notice (DIV), it falls under the general regulatory/news announcement category, which is RNS (Regulatory Filings) as the fallback for miscellaneous announcements.
2021-02-02 French
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is titled "Publication du calendrier financier 2021" (Publication of the 2021 financial calendar) and explicitly states, "MedinCell publie aujourd'hui son calendrier financier indicatif pour l'année 2021." It lists future dates for key events like annual results, the General Meeting (Assemblée Générale), and interim results. Since the document's primary purpose is to announce *when* future reports and meetings will occur, rather than being the report itself (like an ER, IR, or 10-K), it fits the definition of announcing the publication of reports. This aligns best with the Report Publication Announcement (RPA) code, which covers announcements regarding the timing or release of company reports. The document length is short (2330 chars), supporting the 'announcement' classification over the full report classification.
2021-02-01 French
Inside Information / Other news releases
Report Publication Announcement Classification · 98% confidence The document is titled "Publication of the 2021 financial calendar" and explicitly states that "MedinCell today published its indicative financial calendar for the year 2021." It lists future dates for key events like Annual results, General Meeting, and Half-Year results. This document is an announcement about the schedule of future corporate reports and meetings, not the reports themselves. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement detailing the publication schedule of other reports strongly suggests a Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because it fits the specific RPA definition better.
2021-02-01 English
Inside Information / Other news releases
Delisting Announcement Classification · 99% confidence The document is an announcement from MedinCell regarding the transfer of its shares from compartment C to compartment B of Euronext Paris, effective January 29, 2021. This action directly relates to a change in the company's stock listing status and market capitalization tiering, which is a structural change to its capital or listing arrangement. While it is not a direct share buyback (POS) or a general capital raise (CAP), it is a significant announcement concerning the structure and listing of its shares on the exchange. Given the options, 'Share Issue/Capital Change' (SHA) is the closest fit as it involves a change in the structure of how the shares are traded/classified on the exchange, although 'Regulatory Filings' (RNS) is a possibility if a more specific category is unavailable. However, since the change directly impacts the listing segment based on market capitalization, it is fundamentally a capital/listing structure event. Comparing it to the definitions, it is not a financing activity (CAP), but a change in listing status based on market value. Since there is no specific 'Listing Change' code, and it is a formal announcement about the stock's status, 'SHA' (Share Issue/Capital Change) or 'RNS' (General Regulatory Filing) are the candidates. Given the nature of compartment changes being tied to market capitalization thresholds, it is a structural capital/listing event. I will classify it as 'SHA' as it pertains to the structure of the listed shares, but 'RNS' is a strong secondary option if SHA is interpreted too narrowly as only issuance/splits. Given the context of Euronext compartments being tied to market cap, it is a structural change related to the listed security. I will lean towards RNS as the most appropriate general regulatory announcement for a listing segment change that isn't a direct issuance or repurchase.
2021-01-28 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.